NHM Scientists Discover First-Ever Mineral-Based Treatment for Widespread Disease Using the Structure of Crystals

Based on the structure of cubic zirconium silicate, the innovative treatment opens doors to future mineral-based treatments made possible by cutting-edge museum science

Los Angeles, CA (March 26, 2024) — In a groundbreaking discovery, scientists at the Natural History Museum of Los Angeles County and pharmaceutical firm AstraZeneca have published the first-ever mineral-based treatment for a widespread disease. Reported in the journal PLOS One, the study by mineralogist Dr. Aaron Celestian, Curator of Mineral Sciences at NHM, and pharmaceutical chemist  Dr. Jason Lively, opens the door to more advanced mineral-based treatments in the future.

Aaron Celestian (right) analyzing crystals on the scanning electron microscope
Aaron Celestian (right) analyzing crystals on the scanning electron microscope

The paper describes how crystals have been used as a new treatment for hyperkalemia, a disease that affects roughly 350 million people across the planet. Hyperkalemia strikes when a person has too much potassium in their blood and cannot regulate potassium levels. It can result in cardiac arrest in acute cases or cause kidney and liver dysfunction or failure in persistent cases that last decades. 
 

Cubic zirconium crystal structures examined under NHM's scanning electronmicroscope
Cubic zirconium crystal structures examined under NHM's scanning electronmicroscope
Aaron Celestian

“For people suffering from hyperkalemia, the biological processes that regulate potassium in the body are not working optimally, so they have to constantly manage their condition through medications that have potentially harmful side effects and dietary restrictions,” says Celestian. 

The new treatment lets patients flush the excess potassium through ion transfer. “The crystals find the potassium,  absorb it, and then excess gets filtered out of the body through the kidneys,”  says Celestian.

An illustration of part of a 3MR showing how the double lever mechanisms works in CZS-(Na,H).
Fig 18 from the study. An illustration of part of a 3MR showing how the double lever mechanisms works in CZS-(Na,H).


The researchers used the crystal structure of cubic zirconium silicate to develop a treatment without harmful biological interaction—and associated negative side effects.  This is a new way to alleviate deleterious effects on patients that other treatments have.

“It’s like material engineering using minerals as a template,” says Celestian. “Nature’s already grown incredible tools for treating illnesses, and we’re only just beginning to harness those tools.”

Besides having significantly less biological interaction, mineral-based therapies might offer the chance for more durable treatments. Using the structure of crystals means that similar treatments could potentially overcome mutations that make things like viruses so difficult to treat effectively. 

“Minerals probably don’t care about how a virus mutates, as long as it has those building block proteins that the mineral likes to interact with,” says Celestian.


MEDIA CONTACTS

Amy Hood
213-763-3532
ahood@nhm.org

Tyler Hayden
213-763-3508
thayden@nhm.org